Advantage of Novel DES Over BMS Grows With Time

ACC Conference Reporter

TCT 2016 | Washington, DC — A novel polymer-free drug-eluting stent (DES) used with just 1 month of a dual antiplatelet regimen remained safer and became even more effective than a bare-metal stent (BMS) for high bleeding risk patients with additional follow-up in the LEADERS FREE trial. Read More >>>

Keywords: Transcatheter Cardiovascular Therapeutics

< Back to Listings